natgillin/translations-raw huggingface dataset:
The subcutaneous formulation of tildrakizumab showed an absolute bioavailability ranging from 73% (90% CI: 46% - 115%, 200 mg SC vs. 3 mg/kg IV) to 80% (90% CI: 62% - 103%, 50 mg SC vs. 0.5 mg/kg IV) in healthy subjects, as a result of cross study single dose comparison. 
Subkutana formulacijo tildrakizumaba je pokazala absolutno biološko razpoložljivost v razponu od 73 % (90-% IZ: 46 % - 15 %, 200 mg s.c. v primerjavi s 3 mg/kg i.v.)
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON - PACK SIZE 1 PRE-FILLED SYRINGE 
PODATKI NA ZUNANJI OVOJNINI ZUNANJA ŠKATLA - VELIKOST PAKIRANJA 1 NAPOLNJENA INJEKCIJSKA BRIZGA
Renal or hepatic impairment 
Ledvična ali jetrna okvara
- The other ingredients are L-histidine, L-histidine hydrochloride monohydrate, polysorbate 80, 
- Druge sestavine so L-histidin, L-histidinijev klorid monohidrat, polisorbat 80, saharoza in voda za injekcije.
• Gently pinch your skin at the chosen injection site. 
• Kožo na izbranem mestu injiciranja nežno stisnite.
Infections and infestations Upper respiratory tract infectionsa Very common Nervous system disorders Headache 
Infekcijske in parazitske bolezni okužbe zgornjih dihala
Write down the date of removal from the refrigerator in the space provided on the outer carton and appropriate discard date. 
V okence na škatli zabeležite datum, ko ste zdravilo, vzeli iz hladilnika, in ustrezni datum, ko ga je treba zavreči.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON - PACK SIZE 2 PRE-FILLED SYRINGES 
PODATKI NA ZUNANJI OVOJNINI ZUNANJA ŠKATLA - VELIKOST PAKIRANJA 2 NAPOLNJENI INJEKCIJSKI BRIZGI
• Read the Ilumetri Package Leaflet to learn more about your medicine. 
• Če želite izvedeti več o tem zdravilu, preberite navodilo za uporabo zdravila Ilumetri, priloženo pakiranju.
How to store Ilumetri 
Shranjevanje zdravila Ilumetri
Contents of the pack and other information 
Shranjevanje zdravila Ilumetri Vsebina pakiranja in dodatne informacije
200 mg 100 mg Etanercep t reSURFACE1 
28 teden (3 odmerki)* 200 mg 100 mg Placebo Etanercept 200 mg 100 mg Etanercept reSURFACE1
The instructions for using the pre-filled syringes, included with the package leaflet, must be followed carefully. 
Natančno upoštevajte navodila za uporabo napolnjenih injekcijskih brizg, vključena v navodilu za uporabo.
Description of selected adverse reaction Immunogenicity 
Opis izbranih neželenih učinkov
Long term responsea,b 200 mg 
Dolgoročni odziva,b
Comprehensive instructions for administration are given in the package leaflet. 
Izčrpna navodila za dajanje so v navodilu za uporabo.
Keep the product in the original carton in order to protect from light until the time of use. 
Do uporabe shranjujte v originalni ovojnini za zagotovitev zaščite pred svetlobo.
Ilumetri 100 mg solution for injection in pre-filled syringe tildrakizumab 
Ilumetri 100 mg raztopina za injiciranje v napolnjeni injekcijski brizgi tildrakizumab
No effects on fertility parameters such as reproductive organs, menstrual cycle length, and/or hormones were observed in male and female cynomolgus monkeys that were administered tildrakizumab at doses resulting in >100 times the human exposure at the recommended clinical dose based on AUC. 
Pri samcih in samicah opic cynomolgus, ki so jim dajali tildrakizumab v odmerkih, ki so povzročili >100-kratno izpostavljenost priporočenim kliničnim odmerkom pri ljudeh na podlagi AUC, niso opazili nobenih učinkov na parametre plodnosti, kot so reproduktivni organi, dolžina menstrualnega cikla in/ali hormoni.
- The active substance is tildrakizumab. 
- Učinkovina je tildrakizumab.
Renal and Hepatic impairment 
Ledvična in jetrna okvara
39.4c a Co-primary efficacy endpoint at week 12. b Non responder imputation for missing data. 
39,4c a Sočasni opazovani dogodek učinkovitosti v 12 tednu.
INJECTION 
Injiciranje
• Inspect Ilumetri visually for particulate matter and discoloration prior to administration. 
• Zdravilo Ilumetri pred dajanjem vizualno preglejte, da se prepričate, da ne vsebuje trdih delcev oz. da ni obarvano.
The solution is clear to slightly opalescent and colourless to slightly yellow. 
Raztopina je bistra do rahlo opalescentna in brezbarvna do rahlo rumenkasta.
• Choose an injection site with clear skin and easy access such as abdomen, thighs or upper arm. - DO NOT administer 5 cm around the navel or where the skin is tender, bruised, abnormally red, hardened or affected by psoriasis. 
• Izberite mesto injiciranja s čisto kožo, ki je enostavno dosegljivo, na primer trebuh, stegna ali nadlaket.
- Ilumetri is a clear to slightly opalescent and colourless to slightly yellow solution. 
- Zdravilo Ilumetri je je bistra do nekoliko motna in brezbarvna do rahlo rumenkasta raztopina.
Ilumetri is a clear to slightly opalescent and colourless to slightly yellow solution. 
Zdravilo Ilumetri je bistra do rahlo opalescentna in brezbarvna do rahlo rumenkasta raztopina.
Back pain 
Pogosti bolečina v hrbtu
Keep the pre-filled syringes in the outer carton in order to protect from light until the time of use. 
Napolnjene injekcijske brizge do uporabe shranjujte v zunanji ovojnini za zagotovitev zaščite pred svetlobo.
Do not shake or freeze the pre-filled syringe. 
Injekcijske brizge ne stresajte in ne zamrzujte.
Tildrakizumab was shown to distribute across the placental barrier. 
Pokazalo se je, da se tildrakizumab prehaja skozi posteljico.
• On a clean, well-lit work surface, place the: - alcohol wipes - cotton ball or gauze pad 
- alkoholni zloženec, - kosem vate ali zloženec iz gaze, - lepljivi obliž, - zbiralnik za ostre predmete.
The European Commission granted a marketing authorisation valid throughout the European Union for Luminity on 20 September 2006. 
Evropska komisija je dovoljenje za promet z zdravilom Luminity, veljavno po vsej Evropski uniji, izdala 20. septembra 2006.
The gas is then cleared through the lungs. 
Plin se nato očisti skozi pljuča.
There have been five main studies of Luminity, involving a total of 401 patients. 
Opravljenih je bilo pet glavnih študij zdravila Luminity, v katerih je skupaj sodeloval 401 bolnik.
What measures are being taken to ensure the safe and effective use of Luminity? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Luminity?
The full EPAR for Luminity can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Luminity je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
As all five original studies were carried out with a technique known as ‘fundamental' ultrasound imaging, the company also presented the results of some studies to show that the results seen using fundamental imaging could also be obtained when using the imaging techniques known as ‘harmonic' and ‘non linear'. 
Ker je bilo vseh pet prvotnih študij opravljenih s tehniko, znano kot „osnovni“ način ultrazvočnega slikanja, je družba predstavila tudi rezultate nekaterih študij, da bi dokazala, da je rezultate, vidne z osnovnim ultrazvočnim slikanjem, možno dobiti tudi z uporabo tehnik, znanih kot „harmonične“ in „nelinearne“ metode.
Other information about Luminity 
Druge informacije o zdravilu Luminity
This is a summary of the European public assessment report (EPAR) for Luminity. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Luminity.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Luminity have been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo zdravstveni delavci in bolniki upoštevati za varno in učinkovito uporabo zdravila Luminity, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
The most common side effects with Luminity (seen in between 1 and 10 patients in 100) are headache and flushing (reddening of the skin). 
Najpogostejša neželena učinka zdravila Luminity (opažena pri 1 do 10 bolnikih od 100) sta glavobol in zardevanje (pordelost kože).
What benefit has Luminity shown during the studies? 
Kakšne koristi je zdravilo Luminity izkazalo med študijami?
For full details, see the summary of product characteristics (also part of the EPAR). 
Za več informacij glejte povzetek glavnih značilnosti zdravila (ki je prav tako del EPAR).
This ensures that the medicine is shaken in the correct way and for long enough to make up a ‘dispersion' of microspheres of perflutren gas of the right size to get a good quality image. 
S tem se zagotovi, da se zdravilo stresa na pravilen način in dovolj dolgo, s čimer se ustvari „disperzija“ mikrosfer plina perflutrena pravilne velikosti, ki omogoči kakovostno sliko.
It is a contrast agent (a medicine that helps obtain better images of organs and tissues during a scan). 
Je kontrastno sredstvo (zdravilo, ki zagotavlja boljše slike organov in tkiv med slikanjem).
This helps to obtain a better contrast between the area where the gas bubbles are (such as the heart chambers) and the surrounding tissue. 
S tem dobimo boljši kontrast med področjem, kjer so mehurčki plina (npr. v srčnih votlinah), in okoliškim tkivom.
Luminity should only be given by doctors trained in performing and reading images obtained with contrast echocardiography, in hospitals or clinics where appropriate resuscitation equipment is available in case of heart or lung problems or allergic reactions. 
Zdravilo Luminity smejo predpisovati le zdravniki, usposobljeni za slikanje in razlago slik, pridobljenih s kontrastno ehokardiografijo, v bolnišnici ali kliniki, kjer je na razpolago oprema za oživljanje v primeru srčnih ali pljučnih težav ali alergijskih reakcij.
For more information about treatment with Luminity, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist 
Za več informacij o zdravljenju z zdravilom Luminity preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
The last two studies were set up primarily to look at the ability of Luminity to improve the accuracy of the measurement of the ejection fraction (the percentage of the blood volume that is pumped out of the heart in one beat). 
Namen zadnjih dveh študij je bil predvsem proučiti sposobnost zdravila Luminity pri izboljševanju natančnosti meritev iztisnega deleža (odstotek volumna krvi, ki ga srce iztisne ob enem utripu).
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Luminity. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Luminity was effective in enhancing the image of the left ventricle, and it was more effective than placebo in the studies where Luminity and placebo were compared. 
Zdravilo Luminity je bilo učinkovito pri ojačevanju slike levega prekata in učinkovitejše od placeba v študijah, v katerih so primerjali zdravilo Luminity in placebo.
Luminity is for diagnostic use only. 
Zdravilo Luminity je namenjeno samo za diagnostične namene.
The CHMP decided that Luminity's benefits are greater than its risks and recommended that it be given marketing authorisation. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila Luminity večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The way Luminity is given and the dose depend on the technique being used for the echocardiography. 
Način uporabe zdravila Luminity in odmerki so odvisni od uporabljene tehnike za ehokardiografijo.
These studies also looked at left ventricle image enhancement. 
V teh študijah pa so proučevali tudi ojačevanje slike levega prekata.
Before use, Luminity must be activated by shaking it using a mechanical device called Vialmix, which is supplied to doctors who need to prepare the medicine. 
Pred uporabo je treba zdravilo Luminity aktivirati z mehanično napravo za stresanje (Vialmix), ki jo dobijo zdravniki, ki morajo pripraviti zdravilo.
What is the risk associated with Luminity? 
Kakšna tveganja so povezana z zdravilom Luminity?
Luminity perflutren-containing lipid microspheres 
Luminity lipidne mikrosfere, ki vsebujejo perflutren
During echocardiography, the perflutren microspheres in Luminity reflect ultrasound waves differently from the surrounding tissues. 
Med ehokardiografijo mikrosfere perflutrena, vsebovane v zdravilu Luminity, odbijajo ultrazvočne valove drugače kot okoliška tkiva.
For the full list of all side effects and restrictions with Luminity, see the package leaflet. 
Za celoten seznam vseh neželenih učinkov in omejitev pri uporabi zdravila Luminity glejte navodilo za uporabo.
In two of these studies, Luminity was compared with placebo (a dummy treatment). 
V dveh študijah pa so zdravilo Luminity primerjali s placebom (zdravilom brez zdravilne učinkovine).
This is then given into a vein either as a ‘bolus' injection (given all at once) or as an infusion after being diluted. 
Ta se nato da v veno kot „bolusna“ injekcija (bolnik prejme celo injekcijo naenkrat) ali kot infuzija po razredčenju.
When Luminity is injected, it travels in the veins to the heart. 
Po injiciranju zdravilo Luminity potuje po žilah do srca.
Luminity is a solution for injection or infusion (drip) into a vein that contains microspheres (tiny bubbles) of perflutren gas as the active substance. 
Zdravilo Luminity je raztopina za injiciranje ali infundiranje (kapalno infuzijo) v veno, ki vsebuje mikrosfere (majcene mehurčke) plina perflutrena kot zdravilne učinkovine.
Why has Luminity been approved? 
Zakaj je bilo zdravilo Luminity odobreno?
Luminity is used in adults to obtain a clearer image of the chambers of the heart, especially of the left ventricle, during echocardiography (a diagnostic test where an image of the heart is obtained using ultrasound). 
Zdravilo Luminity se uporablja pri odraslih za doseganje jasnejše slike srčnih votlin, zlasti levega prekata, med ehokardiografijo (diagnostičnim pregledom srca, pri katerem sliko srca dobimo z ultrazvokom).
Luminity is used in patients with suspected or confirmed coronary artery disease (obstruction of the blood vessels supplying the heart muscle), when the image obtained without a contrast agent is not good enough. 
Zdravilo Luminity se uporablja pri bolnikih s potrjeno ishemično boleznijo ali sumom nanjo (zaporo v krvnih žilah, ki oskrbujejo srčno mišico), kadar slika, izdelana brez kontrastnega sredstva, ni dovolj dobra.
Three studies looked at its ability to enhance the image of the left ventricle, comparing the echocardiography scan before and after administration of Luminity. 
V treh študijah so proučevali sposobnost zdravila za ojačitev slike levega prekata, in sicer s primerjanjem ehokardiografskih posnetkov pred uporabo zdravila Luminity in po njem.
How has Luminity been studied? 
Kako je bilo zdravilo Luminity raziskano?
What is Luminity used for? 
Za kaj se zdravilo Luminity uporablja?
What is Luminity? 
Kaj je zdravilo Luminity?
How is Luminity used? 
Kako se zdravilo Luminity uporablja?
How does Luminity work? 
Kako zdravilo Luminity deluje?
2 carton pack. 
Pakiranje z dvema škatlama.
Content (concentration) 
Pot uporabe Ovojnina Vsebina (koncentraci ja)
40 mg/0.8 ml 
Velikost pakiranja mg/0,8 ml raztopina za injiciranje viala (steklo) 0,8 ml (40 mg / 0,8 ml)
Route of Administration 
Številka EU
2 pre-filled syringes + 2 
2 napolnjeni injekcijski brizgi s ščitnikom za iglo + 2 alkoholna zloženca
1 alcohol pad 
1 viala +
MA (EU) number (Invented) name Strength Pharmaceutical Form 
Jakost Farmacevtska oblika
Each carton contains: 1 vial + 1 syringe + 1 needle + 1 sterile adapter + 2 alcohol pads 
6 napolnjenih injekcijskih brizg s ščitnikom za iglo + 6 alkoholnih zložencev
Pack size 
Izmišljeno ime
This summary was last updated in 04-2011. 
Povzetek je bil nazadnje posodobljen 04-2011.
As the company had supplied the additional information requested, the ‘exceptional circumstances' ended on 04 July 2008. 
Ker je družba predložila zahtevane dodatne informacije, so „izjemne okoliščine“ prenehale veljati 4. julija 2008.
The main measure of effectiveness was the overall response to treatment. 
Glavno merilo učinkovitosti je bil splošen odziv na zdravljenje.
This is called ‘dose escalation'. 
Ta postopek se imenuje „stopnjevanje odmerka“.
After this, the recommended dose is 30 mg three times a week (every other day) for a maximum of 12 weeks. 
Po tem obdobju je priporočeni odmerek 30 mg trikrat tedensko (vsak drugi dan), ki se jemlje največ 12 tednov.
MabCampath was originally authorised under ‘exceptional circumstances', because, for scientific reasons, it had not been possible to obtain complete information on the medicine. 
Zdravilo MabCampath je bilo prvotno odobreno „v izjemnih okoliščinah“, saj zaradi znanstvenih razlogov ni bilo mogoče pridobiti vseh informacij o zdravilu.
The full EPAR for MabCampath can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo MabCampath je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
The marketing authorisation holder is Genzyme Europa BV. 
Imetnik dovoljenja za promet je družba Genzyme Europe BV.
The European Commission granted a marketing authorisation valid throughout the European Union for MabCampath on 6 July 2001. 
Evropska komisija je dovoljenje za promet z zdravilom MabCampath, veljavno po vsej Evropski uniji, odobrila dne 6. julija 2001.
This is a summary of the European public assessment report (EPAR) for MabCampath. 
Ta dokument je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo MabCampath.
• who have an active infection that has spread throughout the body; • with HIV infection; 
• bolnikih z aktivno okužbo, ki se je razširila po vsem telesu;
MabCampath is given as an infusion lasting about two hours. 
Zdravilo MabCampath se daje kot infuzija, ki traja približno 2 uri.
The main measure of effectiveness was how long it took until the disease got worse or the patient died. 
Glavno merilo učinkovitosti je bil čas, v katerem se je bolniku bolezensko stanje poslabšalo, oziroma čas do smrti bolnika.
In the patients receiving MabCampath, it took an average of 14.6 months for the disease to get worse or for the patient to die, compared with 11.7 months in those taking chlorambucil. 
Pri bolnikih, ki so prejemali zdravilo MabCampath, je v povprečju trajalo 14,6 meseca, da se je bolezensko stanje poslabšalo ali da je bolnik umrl, pri tistih, ki so jemali klorambucil, pa je to obdobje trajalo 11,7 meseca.
During the first week of treatment, MabCampath should be given in increasing doses: 3 mg on day 1, 10 mg on day 2 and 30 mg on day 3, as long as each dose is well tolerated. 
Med prvim tednom zdravljenja je treba odmerek zdravila MabCampath povečevati: prvi dan 3 mg, drugi dan 10 mg in tretji dan 30 mg, vse dokler bolnik dani odmerek še dobro prenaša.
In the study of patients who had been treated with fludarabine before, 33% responded partially or completely to treatment with MabCampath. 
V študiji bolnikov, ki so predhodno že bili zdravljeni s fludarabinom, se je na zdravljenje z zdravilom MabCampath delno ali popolnoma odzvalo 33 % bolnikov.
The most frequent serious adverse reactions are low counts of blood cells, infusion reactions, and infections or immunosuppression (reduced activity of the immune system). 
Najpogostejše neželene resne reakcije so nizko število krvnih celic, reakcije na infundiranje in okužbe ali imunosupresija (oslabljeno delovanje imunskega sistema).
In these studies, MabCampath was not compared with any other treatment. 
V teh študijah zdravila MabCampath niso primerjali z nobenim drugim zdravilom.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo MabCampath, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
The most frequent side effects with MabCampath are: infusion reactions (fever, chills, low blood pressure, itching, feeling sick, hives, increased heart rate, breathlessness), low counts of blood cells (white blood cells, platelets and red blood cells), infections (signs of cytomegalovirus in the blood, cytomegalovirus infection or other infections), gastrointestinal symptoms (feeling sick, vomiting, abdominal pain) and neurological symptoms (insomnia, anxiety). 
Najpogostejši neželeni učinki zdravila MabCampath so: reakcije na infundiranje (povišana telesna temperatura, mrzlica, nizek krvni tlak, srbečica, slabost, srbeči izpuščaji, povišan srčni utrip, oteženo dihanje), nizko število krvnih telesc (belih krvničk, krvnih ploščic in rdečih krvničk), okužbe (znaki prisotnosti citomegalovirusa v krvi, okužbe s citomegalovirusom ali druge okužbe), gastrointestinalni simptomi (slabost, bruhanje, bolečine v trebuhu) in nevrološki simptomi (nespečnost, anksioznost).
Patients should be monitored during treatment to see how they respond, but also to check their blood levels of platelets (components that help the blood to clot) and neutrophils (a type of white blood cell that fights infection): if these are too low the treatment should be interrupted or stopped. 
Bolnike je treba med zdravljenjem spremljati, da bi videli kako se odzivajo, pa tudi da bi preverili njihove krvne ravni trombocitov (krvnih ploščic, ki pomagajo pri strjevanju krvi) in nevtrofilcev (belih krvnih telesc, ki se borijo proti okužbam): če so te prenizke, je treba zdravljenje začasno ali trajno prekiniti.
One study included 297 patients who had not received treatment before. 
Ena študija je vključevala 297 bolnikov, ki predhodno še niso bili zdravljeni.
The company that makes MabCampath will provide a brochure containing information on the medicine's safety to all doctors in all Member States who prescribe the medicine. 
Družba, ki izdeluje zdravilo MabCampath, bo zdravnikom v vseh državah članicah, ki predpisujejo zdravilo, zagotovila brošuro z informacijami o varnosti zdravila.
What measures are being taken to ensure the safe use of MabCampath? 
Kateri ukrepi se izvajajo za zagotovitev varne uporabe zdravila MabCampath?
The other three studies looked at a total of 149 patients who had already received other treatments. 
Druge tri študije so vključevale skupno 149 bolnikov, ki so že prejeli druge vrste zdravljenja.
For more information about treatment with MabCampath, read the package leaflet (also part of the EPAR) or contact your doctor or 
Za več informacij o zdravljenju z zdravilom MabCampath preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
MabCampath treatment should be supervised by a doctor experienced in the use of cancer treatments. 
Zdravljenje z zdravilom MabCampath mora nadzorovati zdravnik, ki ima izkušnje z zdravljenjem raka.
In patients who had not received treatment before, MabCampath was more effective than chlorambucil. 
Pri bolnikih, ki predhodno še niso bili zdravljeni, je bilo zdravilo MabCampath učinkovitejše od klorambucila.
Alemtuzumab has been designed to attach to a glycoprotein (a protein that is coated with sugar molecules) called CD52 that is found on the surface of lymphocytes. 
Alemtuzumab je bil zasnovan tako, da se veže na glikoprotein (beljakovino, ki je obdana z molekulami sladkorja), imenovan CD52, ki ga najdemo na površini limfocitov.
What benefit has MabCampath shown during the studies? 
Kakšne koristi je zdravilo MabCampath izkazalo med študijami?